Immune Thrombocytopenic Purpura

9
Pipeline Programs
7
Companies
10
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
1
1
1
5
1
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

6 companies ranked by most advanced pipeline stage

CSL Behring
CSL BehringIL - Bradley
2 programs
1
1
IgPro10Phase 41 trial
Immunoglobulin IntravenousPhase 31 trial
Active Trials
NCT00168038Completed58Est. Feb 2006
NCT01390649Completed57Est. Sep 2014
Rigel Pharmaceuticals
Rigel PharmaceuticalsSOUTH SAN FRANCISCO, CA
4 programs
3
Fostamatinib DisodiumPhase 31 trial
Fostamatinib DisodiumPhase 31 trial
Fostamatinib disodiumPhase 31 trial
Fostamatinib disodium 100 mgN/A1 trial
Active Trials
NCT03363334No Longer Available
NCT02077192CompletedEst. Jun 2020
NCT02076412CompletedEst. Aug 2016
+1 more trials
Octapharma
OctapharmaAustria - Vienna
1 program
1
Octagam 10%Phase 31 trial
Active Trials
NCT00426270Completed116Est. Sep 2008
Biogen
BiogenCAMBRIDGE, MA
1 program
1
Rituxan, Cyclophosphamide, Vincristine, PrednisonePhase 2/31 trial
Active Trials
NCT00774202Completed17Est. Feb 2008
Swedish Orphan Biovitrum
1 program
1
Sym001Phase 21 trial
Active Trials
NCT00718692CompletedEst. Oct 2011
Bristol Myers Squibb
1 program
1
BMS-986004 75 mg IVPhase 1/21 trial
Active Trials
NCT02273960Completed46Est. Jan 2018

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
CSL BehringIgPro10
Rigel PharmaceuticalsFostamatinib Disodium
Rigel PharmaceuticalsFostamatinib Disodium
Rigel PharmaceuticalsFostamatinib disodium
OctapharmaOctagam 10%
CSL BehringImmunoglobulin Intravenous
BiogenRituxan, Cyclophosphamide, Vincristine, Prednisone
Swedish Orphan BiovitrumSym001
Bristol Myers SquibbBMS-986004 75 mg IV

Clinical Trials (10)

Total enrollment: 294 patients across 10 trials

NCT01390649CSL BehringIgPro10

A Safety Study of Intravenous Immunoglobulin in Patients With Chronic Immune Thrombocytopenic Purpura (ITP)

Start: Nov 2011Est. completion: Sep 201457 patients
Phase 4Completed
NCT02076412Rigel PharmaceuticalsFostamatinib Disodium

A Efficacy and Safety Study of Fostamatinib in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP)

Start: Jan 2015Est. completion: Aug 2016
Phase 3Completed
NCT02077192Rigel PharmaceuticalsFostamatinib Disodium

Open Label Study of R788 in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP)

Start: Oct 2014Est. completion: Jun 2020
Phase 3Completed
NCT02076399Rigel PharmaceuticalsFostamatinib disodium

A Efficacy and Safety Study of R935788 in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP)

Start: Jul 2014Est. completion: Apr 2016
Phase 3Completed
NCT00426270OctapharmaOctagam 10%

Clinical Study to Evaluate the Efficacy and Safety of Octagam 10% in Idiopathic Thrombocytopenic Purpura in Adults

Start: Jun 2006Est. completion: Sep 2008116 patients
Phase 3Completed
NCT00168038CSL BehringImmunoglobulin Intravenous

Treatment of Chronic Immune Thrombocytopenic Purpura (ITP) With Intravenous Immunoglobulin IgPro10

Start: Dec 2004Est. completion: Feb 200658 patients
Phase 3Completed
NCT00774202BiogenRituxan, Cyclophosphamide, Vincristine, Prednisone

Higher Dose of Rituxan Versus Standard Doses of Rituxan With Cyclophosphamide, Vincristine, and Prednisone in Subjects With Chronic ITP

Start: Nov 2003Est. completion: Feb 200817 patients
Phase 2/3Completed
NCT00718692Swedish Orphan BiovitrumSym001

Open Label Trial on the Safety and Efficacy of Sym001 in the Treatment of Immune Thrombocytopenic Purpura (ITP)

Start: Jul 2008Est. completion: Oct 2011
Phase 2Completed
NCT02273960Bristol Myers SquibbBMS-986004 75 mg IV

Study to Evaluate Safety and Efficacy in Adult Subjects With ITP

Start: Nov 2014Est. completion: Jan 201846 patients
Phase 1/2Completed
NCT03363334Rigel PharmaceuticalsFostamatinib disodium 100 mg

Expanded Access of Fostamatinib in Patients With Persistent or Chronic Relapsing/Refractory ITP

N/ANo Longer Available

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

5 late-stage (Phase 3) programs — potential near-term approvals
7 companies competing in this space